- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01408849
Use of Maytenus Ilicifolia in the Treatment of Dyspepsia
July 25, 2016 updated by: Fabio Carmona, Casa Espirita Terra de Ismael
Use of Maytenus Ilicifolia Mart. ex Reiss in the Treatment of Dyspepsia
This study aims to evaluate the therapeutic effect of the infusion of Maytenus ilicifolia Mart.
ex Reiss leaves, used for 8 weeks, on patients with dyspepsia.
Primary endpoint is SODA score, secondary endpoint is endoscopic classification (Sydney).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
Ribeirao Preto, SP, Brazil, 14049-900
- Hospital das Clínicas FMRP-USP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age > 18 years
- being literate
- diagnosis of dyspepsia
- initial SODA score > or = 25
Exclusion Criteria:
- pregnancy
- lactation
- allergy to Maytenus species
- fail to use the drug for 3 uninterrupted weeks
- new onset serious adverse events, attributable to the drug
- patient's request
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maytenus
Tea of Martens ilicifolia leaves
|
2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
|
Active Comparator: Omeprazole
Omeprazole as active comparator
|
Standard therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SODA score
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sydney classification
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Ana MS Pereira, PhD, University of Ribeirao Preto
- Study Chair: Jose S Santos, MD, PhD, HCFMRP-USP
- Principal Investigator: Fabio Carmona, MD, PhD, HCFMRP-USP
- Principal Investigator: Suzeidi B Castanheira, MD, PhD, HCFMRP-USP
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
July 29, 2011
First Submitted That Met QC Criteria
August 2, 2011
First Posted (Estimate)
August 3, 2011
Study Record Updates
Last Update Posted (Estimate)
July 26, 2016
Last Update Submitted That Met QC Criteria
July 25, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Maytenus2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of